Substance / Medication

Nimorazole

Overview

Active Ingredient
nimorazole
RxNorm CUI
7427

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup Kasper, Sørensen Brita Singers, Lassen Pernille et al. · Radiother Oncol · 2012
PMID: 21996521RCT
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Musiał-Kulik Monika, Włodarczyk Jakub, Stojko Mateusz et al. · Eur J Pharm Biopharm · 2021
PMID: 33567313Observational
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Sugie Chikao, Shibamoto Yuta, Ito Masato et al. · J Radiat Res · 2005
PMID: 16394636Observational
[A case of toxic encephaloneuropathy during treatment with nimorazole].
Qadir Shanga Hassan, Jakubauskaite Ruta, Laursen Emilie Lund · Ugeskr Laeger · 2025
PMID: 40746124Case Report
The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists.
Bjarnason Nina H, Christiansen Michael, Specht Lena · Acta Oncol · 2008
PMID: 17851836Case Report
Nimorazole may increase the effect of phenprocoumon.
Bjarnason Nina H, Specht Lena, Dalhoff Kim · Radiother Oncol · 2005
PMID: 15763317Case Report
Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
Besso María José, Bitto Verena, Koi Lydia et al. · Radiother Oncol · 2024
PMID: 38823583Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nimorazole (substance)
SNOMED CT
418509004
UMLS CUI
C0028095
RxNorm CUI
7427

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.